![]() |
UMIN-CTR Clinical Trial |
|
![]() |
![]() |
![]() |
![]() |
Name: | UMIN ID: |
Recruitment status | Enrolling by invitation |
Unique ID issued by UMIN | UMIN000043340 |
Receipt No. | R000049480 |
Scientific Title | Research for acquired immunity according to COVID-19 vaccination |
Date of disclosure of the study information | 2021/02/16 |
Last modified on | 2021/02/16 |
Basic information | ||
Public title | Research for acquired immunity according to COVID-19 vaccination | |
Acronym | Research for COVID-19 vaccine immunity | |
Scientific Title | Research for acquired immunity according to COVID-19 vaccination | |
Scientific Title:Acronym | Research for COVID-19 vaccine immunity | |
Region |
|
Condition | ||
Condition | COVID-19 | |
Classification by specialty |
|
|
Classification by malignancy | Others | |
Genomic information | NO |
Objectives | |
Narrative objectives1 | To assess acquisition rate and duration of cellular and humoral immunity after COVID-19 vaccination |
Basic objectives2 | Efficacy |
Basic objectives -Others | |
Trial characteristics_1 | |
Trial characteristics_2 | |
Developmental phase |
Assessment | |
Primary outcomes | acquisition rate of cellular and humoral immunity for SARS-CoV-2 |
Key secondary outcomes |
Base | |
Study type | Observational |
Study design | |
Basic design | |
Randomization | |
Randomization unit | |
Blinding | |
Control | |
Stratification | |
Dynamic allocation | |
Institution consideration | |
Blocking | |
Concealment |
Intervention | |
No. of arms | |
Purpose of intervention | |
Type of intervention | |
Interventions/Control_1 | |
Interventions/Control_2 | |
Interventions/Control_3 | |
Interventions/Control_4 | |
Interventions/Control_5 | |
Interventions/Control_6 | |
Interventions/Control_7 | |
Interventions/Control_8 | |
Interventions/Control_9 | |
Interventions/Control_10 |
Eligibility | ||||
Age-lower limit |
|
|||
Age-upper limit |
|
|||
Gender | Male and Female | |||
Key inclusion criteria | Faculty stuffs and hospital stuffs of Keio University Shinanomachi campus
Vaccinated or planned to be vaccinated for COVID-19 vaccine Capable for informed consent and blood collection |
|||
Key exclusion criteria | Minors
Contraindicated for vaccination |
|||
Target sample size | 300 |
Research contact person | |||||||
Name of lead principal investigator |
|
||||||
Organization | Keio University School of Medicine | ||||||
Division name | Department of Laboratory Medicine | ||||||
Zip code | 1608582 | ||||||
Address | 35 Shinanomachi, Shinjuku-ku, Tokyo | ||||||
TEL | 03-3353-1211 | ||||||
wakuism@keio.jp |
Public contact | |||||||
Name of contact person |
|
||||||
Organization | Keio University School of Medicine | ||||||
Division name | Department of Laboratory Medicine | ||||||
Zip code | 1608582 | ||||||
Address | 35 Shinanomachi, Shinjuku-ku, Tokyo | ||||||
TEL | 03-3353-1211 | ||||||
Homepage URL | |||||||
uwamino@keio.jp |
Sponsor | |
Institute | Keio University |
Institute | |
Department |
Funding Source | |
Organization | Keio University |
Organization | |
Division | |
Category of Funding Organization | Self funding |
Nationality of Funding Organization |
Other related organizations | |
Co-sponsor | |
Name of secondary funder(s) |
IRB Contact (For public release) | |
Organization | Ethics Committee of Keio University School of Medicine |
Address | 35 Shinanomachi, Shinjuku, Tokyo |
Tel | 03-3353-1211 |
med-rinri-jimu@adst.keio.ac.jp |
Secondary IDs | |
Secondary IDs | NO |
Study ID_1 | |
Org. issuing International ID_1 | |
Study ID_2 | |
Org. issuing International ID_2 | |
IND to MHLW |
Institutions | |
Institutions |
Other administrative information | |||||||
Date of disclosure of the study information |
|
Related information | |
URL releasing protocol | |
Publication of results | Unpublished |
Result | |
URL related to results and publications | |
Number of participants that the trial has enrolled | |
Results | |
Results date posted | |
Results Delayed | |
Results Delay Reason | |
Date of the first journal publication of results | |
Baseline Characteristics | |
Participant flow | |
Adverse events | |
Outcome measures | |
Plan to share IPD | |
IPD sharing Plan description |
Progress | |||||||
Recruitment status | Enrolling by invitation | ||||||
Date of protocol fixation |
|
||||||
Date of IRB |
|
||||||
Anticipated trial start date |
|
||||||
Last follow-up date |
|
||||||
Date of closure to data entry | |||||||
Date trial data considered complete | |||||||
Date analysis concluded |
Other | |
Other related information | Design: Prospective
Exposure- COVID-19 Vaccination Outcome- Humoral and Cellular immunity for SARS-CoV-2 Observation:Antibody titer and T cell and B cell immune response to SARS-CoV-2 |
Management information | |||||||
Registered date |
|
||||||
Last modified on |
|
Link to view the page | |
URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049480 |
Research Plan | |
Registered date | File name |
Research case data specifications | |
Registered date | File name |
Research case data | |
Registered date | File name |